title: Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma.
authors: Department of Dermatology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France. Electronic address: charles.cassius@gmail.com.
authors: Charles
authors: C
authors: Cassius
authors: Department of Dermatology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
authors: Cécile
authors: C
authors: Pages
authors: Department of Dermatology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
authors: Jennifer
authors: J
authors: Roux
authors: Department of Dermatology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
authors: Raphael
authors: R
authors: Lhote
authors: Department of Plastic Surgery, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
authors: Romain
authors: R
authors: Lavocat
authors: Department of Hematology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
authors: Delphine
authors: D
authors: Réa
authors: Department of Dermatology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
authors: Martine
authors: M
authors: Bagot
authors: INSERM U976 and Univ Paris Diderot, Sorbonne Paris Cité, Paris, France.
authors: Samia
authors: S
authors: Mourah
authors: Department of Pathology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
authors: Maxime
authors: M
authors: Battistella
authors: Department of Dermatology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France; INSERM U976 and Univ Paris Diderot, Sorbonne Paris Cité, Paris, France.
authors: Céleste
authors: C
authors: Lebbé
authors: INSERM U976 and Univ Paris Diderot, Sorbonne Paris Cité, Paris, France.
authors: Nicolas
authors: N
authors: Dumaz
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced*; D005260:Female; D011905:Genes, ras; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D010885:Pipobroman / Q000009:adverse effects*; D055503:Protein Multimerization / Q000187:drug effects*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000737:chemistry*; D012878:Skin Neoplasms / Q000139:chemically induced*; D013449:Sulfonamides / Q000009:adverse effects*; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; D010885:Pipobroman; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf